Lubna Akhtar
Overview
Explore the profile of Lubna Akhtar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
127
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hussain M, Atif M, Babar M, Akhtar L
J Ayub Med Coll Abbottabad
. 2022 Feb;
33(4):593-597.
PMID: 35124914
Background: SGLT-2 (sodium-glucose cotransporter-2) inhibitors are a novel class of oral hypoglycemic agents for the management of type 2 diabetes mellitus (T2DM). Herein, we aimed to assess the efficacy and...
2.
Majid A, Javed A, Hussain M, Faisal Z, Elahi A, Akhtar L
Pak J Pharm Sci
. 2021 Nov;
34(5(Supplementary)):1891-1895.
PMID: 34836856
Blood pressure control in hypertensive patients with metabolic abnormalities is challenging because many antihypertensive drugs adversely affect metabolism. Nebivolol a 3rd generation vasodilatory β-blocker offer neutral or beneficial effects on...
3.
Hussain M, Elahi A, Hussain A, Iqbal J, Akhtar L, Majid A
J Diabetes Res
. 2021 Jul;
2021:9973862.
PMID: 34239940
Background: Hyperuricemia has a strong association with diabetes mellitus. Hyperuricemia can lead to cardiovascular and renal complications in patients with diabetes. The goal of this study was to compare the...
4.
Babar M, Hussain M, Ahmad M, Akhtar L
J Ayub Med Coll Abbottabad
. 2021 Jun;
33(2):188-191.
PMID: 34137526
Background: Type 2 diabetes mellitus (T2DM) is a progressive disease due to multiple pathophysiological defects. Monotherapy alone cannot achieve adequate glycemic control and can lead to treatment failure. Empagliflozin, a...
5.
Hussain M, Iqbal J, Malik S, Waheed A, Shabnum S, Akhtar L, et al.
Pak J Pharm Sci
. 2019 Sep;
32(3 Special):1343-1348.
PMID: 31551213
There are still no FDA approved drugs for NAFLD so far. Vitamin D may be a good therapeutic option for NAFLD patients due to its insulin sensitizing and anti-inflammatory properties....
6.
Hussain M, Rafique M, Iqbal J, Akhtar L
Pak J Med Sci
. 2019 May;
35(2):383-387.
PMID: 31086519
Objectives: To compare the anti-inflammatory effect of sitagliptin and glimepiride by measuring CRP in overweight Type-2 diabetic patients. Methods: This clinical trial was conducted at diabetic clinic of Islam Central...
7.
Hussain M, Babar M, Akhtar L, Hussain M
Pak J Med Sci
. 2018 Mar;
33(6):1366-1370.
PMID: 29492060
Background And Objective: Increased neutrophil lymphocyte ratio (NLR) is a marker as well as predictor of various cardiac and non cardiac disorders. Our aim was to assess the relationship between...
8.
Hussain M, Shad M, Akhtar L
J Pak Med Assoc
. 2017 Dec;
67(12):1884-1888.
PMID: 29256535
Objective: To determine the effect of pioglitazone on cardiometabolic risk factors in non-diabetic patients with dyslipidaemia. Methods: This prospective, randomised clinical trial was conducted at Sheikh Zayed Medical College and...
9.
Hussain M, Tunio A, Akhtar L, Shaikh G
J Ayub Med Coll Abbottabad
. 2017 Oct;
29(3):403-407.
PMID: 29076670
Background: Non-alcoholic Fatty Liver disease (NAFLD) is the most common cause of progressive liver disorders worldwide. Drug options are limited with varying results. Nigella sativa in the form of herbal...
10.
Hussain M, Habib-Ur-Rehman , Akhtar L
Pak J Med Sci
. 2017 Oct;
33(4):931-936.
PMID: 29067068
Background And Objective: NAFLD affecting up to 30% of the population globally. Drug treatment options are limited with disappointing results. The dietary supplementation in the form of green tea is...